Date: 2015-12-05
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando
Company: GlycoMimetics (USA - Md)
Product: GMI-1271
Action mechanism: E-selectin antagonist. GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with acute myeloid leukemia cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy.
Disease: acute myeloid leukemia (AML)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: • On December 5, 2015, GlycoMimetics presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting first-in-human Phase 1 results that showed a favorable safety, pharmacokinetic and biomarker profile for GMI-1271, which is being investigated as a treatment for acute myeloid leukemia (AML) and other blood cancers. The data presented at ASH, prepared by researchers at GlycoMimetics and the University of Michigan, is from two Phase 1 studies of 52 healthy volunteers. It showed that GMI-1271 was well tolerated with no serious adverse effects, demonstrating increased concentrations in plasma that were dose-dependent. Several key biomarker findings supportive of the targeted mechanism of the drug were reported, including the absence of any increase in bleeding times compared to low molecular weight heparin and the absence of a rise in CD34+ hematopoietic stem cells (an indication that the compound does not adversely stimulate the bone marrow to release primitive cells). In addition, increasing doses of GMI-1271 significantly reduced levels of the biomarker E-selectin, a cell adhesion molecule that binds to cancer cells and is a key component of drug resistance by blood cancers.
